Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Alx Oncology Holdings (ALXO) Net Income towards Common Stockholders (2019 - 2023)

Alx Oncology Holdings' Net Income towards Common Stockholders history spans 5 years, with the latest figure at $91.1 million for Q4 2023.

  • For Q4 2023, Net Income towards Common Stockholders rose 397.18% year-over-year to $91.1 million; the TTM value through Dec 2023 reached -$24.7 million, up 80.0%, while the annual FY2025 figure was -$497000.0, 99.63% up from the prior year.
  • Net Income towards Common Stockholders for Q4 2023 was $91.1 million at Alx Oncology Holdings, up from -$51.0 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $91.1 million in Q4 2023 and bottomed at -$51.0 million in Q3 2023.
  • The 5-year median for Net Income towards Common Stockholders is -$18.8 million (2020), against an average of -$15.8 million.
  • The largest annual shift saw Net Income towards Common Stockholders tumbled 169.83% in 2020 before it surged 397.18% in 2023.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$8.8 million in 2019, then tumbled by 112.5% to -$18.8 million in 2020, then tumbled by 51.48% to -$28.4 million in 2021, then decreased by 7.75% to -$30.6 million in 2022, then soared by 397.18% to $91.1 million in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Net Income towards Common Stockholders are $91.1 million (Q4 2023), -$51.0 million (Q3 2023), and -$34.5 million (Q2 2023).